Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis LEUKEMIA Landau, H., Smith, M., Landry, C., Chou, J. F., Devlin, S. M., Hassoun, H., Bello, C., Giralt, S., Comenzo, R. L. 2017; 31 (1): 136-142

Abstract

Stem cell transplantation (SCT), an effective therapy for amyloid light chain (AL) amyloidosis patients, is associated with low treatment-related mortality (TRM) with appropriate patient selection and risk-adapted dosing of melphalan (RA-SCT). Consolidation after SCT increases hematologic complete response (CR) rates and may improve overall survival (OS) for patients with

View details for DOI 10.1038/leu.2016.229

View details for Web of Science ID 000394058700018

View details for PubMedID 27560108

View details for PubMedCentralID PMC5220129